MedTrace Logo

Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

NCT00995670 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2015-03-17

Study results available
· View outcomes & findings →

Summary

Anesthetic preconditioning (APC, a brief exposure to an anesthetic gas) has become an area of intense research interest because of its ability to protect tissue and organs from injury resulting from a cessation of blood flow and then a re-establishment of flow. The blood vessel lining plays a key role in this injury. This research will examine, in human volunteers, several important modifiers of APC in human blood vessels: high blood sugar, vitamin C, and statin drugs. Thus, the proposed studies will advance the investigators' understanding of mechanisms of this injury in humans and explore important modifiers of APC protection from injury.

Conditions

Interventions

DRUG

5% dextrose

Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.

DRUG

Vitamin C

Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.

DRUG

Simvastatin

Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.

DRUG

Sevoflurane

Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.

Sponsors & Collaborators

Principal Investigators

  • Thomas J Ebert, MD PhD · Zablocki VA Medical Center, Milwaukee

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00995670 on ClinicalTrials.gov